Poxvirus-derived cytokine response modifier A (CrmA) does not protect against focal cerebral ischemia in mice

Brain Research

Volumn 1185, Issue 1, 2007, Pages 293-300

  Kilic, Ertugrul ^a,d   Wippel, Andreas ^b,d   Kilic, Ülkan ^a,d   Vogel, Peter ^b,d   Kim, Mia ^b,d   van der Putten, Herman ^c,d   Wiessner, Christoph ^c,d   Rovelli, Giorgio ^c,d   Böttiger, Bernd W ^b,d   Hermann, Dirk M ^a,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Apoptotic cell death; Caspase inhibitor; Ischemic stroke; TNF receptor family

Indexed keywords

CASPASE 3; CYTOKINE RESPONSE MODIFIER A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CORTEX; BRAIN ISCHEMIA; CHROMOSOME 8; CONTROLLED STUDY; CORPUS STRIATUM; CRMA GENE; ENZYME ACTIVATION; GENE; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENIC MOUSE;

ANIMALS; ANIMALS, NEWBORN; ANTIGENS, THY-1; BEHAVIOR, ANIMAL; BRAIN; BRAIN EDEMA; CASPASE 3; CASPASE 8; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; INFARCTION, MIDDLE CEREBRAL ARTERY; MICE; MICE, TRANSGENIC; SERPINS; VIRAL PROTEINS;

COWPOX VIRUS; MUS; MUS MUSCULUS; POXVIRIDAE;

EID: 36448950548     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.09.031     Document Type: Article

References (25)

1. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
2. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104 (2004) 29-45
3. Evans G.A., Ingraham H.A., Lewis K., Cunningham K., Seki T., Moriuchi T., Chang H.C., Silver J., and Hyman R. Expression of the Thy-1 glycoprotein gene by DNA-mediated gene transfer. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 5532-5536
4. Ferrer I., and Planas A.M. Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra. J. Neuropathol. Exp. Neurol. 62 (2003) 329-339
5. Gerhardt E., Kügler S., Leist M., Beier C., Berliocchi L., Volbracht C., Weller M., Bähr M., Nicotera P., and Schulz J.B. Cascade of caspase activation in potassium-deprived cerebellar granule neurons: targets for treatment with peptide and protein inhibitors of apoptosis. Mol. Cell. Neurosci. 17 (2001) 717-731
6. Hata R., Maeda K., Hermann D., Mies G., and Hossmann K.-A. Dynamics of regional brain metabolism and gene expression after middle cerebral artery occlusion in mice. J. Cereb. Blood Flow Metab. 20 (2000) 306-315
7. Hermann D.M., and Bassetti C.L. Implications of ATP-binding cassette transporters for brain pharmacotherapies. Trends Pharmacol. Sci. 28 (2007) 128-134
8. Hermann D.M., and Bassetti C.L. Neuroprotection in the SAINT-II aftermath. Ann. Neurol. (2007) (Sep 11)
9. Hermann D.M., Kilic E., Hata R., Hossmann K.-A., and Mies G. Relationship between metabolic changes, gene responses and delayed ischemic injury after mild focal cerebral ischemia in mice. Neuroscience 104 (2001) 947-955
10. Hermann D.M., Kilic E., Kügler S., Isenmann S., and Bähr M. Adenovirus-mediated GDNF and CNTF pretreatment protects against striatal injury following transient middle cerebral artery occlusion in mice. Neurobiol. Dis. 8 (2001) 655-666
11. Kilic E., Kilic U., Soliz J., Bassetti C.L., Gassmann M., and Hermann D.M. Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways. FASEB J. 19 (2005) 2026-2028
12. Kilic E., Kilic Ü., Wang Y., Bassetti C.L., Marti H.H., and Hermann D.M. The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J. 20 (2006) 1185-1187
13. Kügler S., Klöcker N., Kermer P., Isenmann S., and Bähr M. Transduction of axotomized retinal ganglion cells by adenoviral vector administration at the optic nerve stump: an in vivo model system for the inhibition of neuronal apoptotic cell death. Gene Ther. 6 (1999) 1759-1767
14. Martin-Villalba A., Herr I., Jeremias I., Hahne M., Brandt R., Vogel J., Schenkel J., Herdegen T., and Debatin K.M. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 19 (1999) 3809-3817
15. Martin-Villalba A., Hahne M., Kleber S., Vogel J., Falk W., Schenkel J., and Krammer P.H. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ. 8 (2001) 679-686
16. Roy M., and Sapolsky R.M. The neuroprotective effects of virally-derived caspase inhibitors p35 and crmA following a necrotic insult. Neurobiol. Dis. 14 (2003) 1-9
17. Ryan C.A., Stennicke H.R., Nava V.E., Burch J.B., Hardwick J.M., and Salvesen G.S. Inhibitor specificity of recombinant and endogenous caspase-9. Biochem. J. 366 (2002) 595-601
18. Savitz S.I., and Fisher M. Future of neuroprotection for acute stroke in the aftermath of the SAINT trials. Ann. Neurol. 61 (2007) 396-402
19. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., and Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17 (1998) 1675-1687
20. Schulz J.B., Weller M., and Moskowitz M.A. Caspases as treatment targets in stroke and neurodegenerative diseases. Ann. Neurol. 45 (1999) 421-429
21. Shuaib A., Lees K.R., Lyden P., Grotta J., Davalos A., Davis S.M., Diener H.C., Ashwood T., Wasiewski W.W., Emeribe U., and SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 357 (2007) 562-571
22. Spudich A., Kilic E., Xing H., Kilic Ü., Rentsch K.M., Wunderli-Allenspach H., Bassetti C.L., and Hermann D.M. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat. Neurosci. 9 (2006) 487-488
23. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30 (1999) 2752-2758
24. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32 (2001) 1598-1606
25. Wang Y., Kilic E., Kilic Ü., Weber B., Bassetti C.L., Marti H.H., and Hermann D.M. VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 128 (2005) 52-63